

ANNIE GUÉRIN
Managing Principal

Phone: 514 394 4484
Mobile: 514 452 1681
annie.guerin@analysisgroup.com

1190 avenue des Canadiens-de-Montréal
Tour Deloitte, Suite 1500
Montreal, Quebec H3B 0G7

Ms. Guérin is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include retrospective database analyses such as medical claims, electronic health records, and clinical trial data; economic modeling, such as cost-effectiveness and budget impact models; and design of chart review studies, surveys, and other prospective studies. She has participated in the development of large clinical data registries and in the design of real-world evidence (RWE) studies to support regulatory submissions. Ms. Guérin has broad research and analytical experience in areas such as comparative effectiveness and cost effectiveness, development of prediction algorithms, assessment of disease prevalence and incidence, evaluation of burden of illness, productivity loss, treatment patterns, analysis of patient-reported outcomes (PROs), safety/tolerability analyses, discrete choice experiments, and patient experience studies. She has also supported many pharmaceutical companies in the development of HEOR planning and RWE generation plans. Ms. Guérin has conducted health care research across many therapeutic areas, including oncology, hematology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology and circulatory diseases, and respiratory diseases. She publishes frequently and is the coauthor of over 100 research papers published in numerous peer-reviewed journals and presented at a variety of scientific conferences.

EDUCATION

- 2005–2008 M.S., economics (*honors*), Université de Sherbrooke, Quebec
Concentration: Pharmacoeconomics/Econometrics
- 2002–2005 B.S., economics (*honors*), Co-op Program, Université de Sherbrooke, Quebec

WORK EXPERIENCE

- 2005–Present Analysis Group/Group d'analyse
Managing Principal (2020–Present)
Vice President (2014–2020)
Senior Economist (2010–2013)
Economist (2006–2009)
Intern (2005–2006)
- 2004 Quebec Revenue Agency, Ste-Foy (Agence Revenu Québec, Ste-Foy)
Intern in Economic and Fiscal Studies
- 2004 Ministry of Economic and Regional Research and Development, Quebec
(Ministère du Développement économique et régional et de la recherche, Québec)
Intern; conducted research on entrepreneurship in Quebec
- 2003 Ministry of Economic and Regional Research and Development, Quebec
(Ministère du Développement économique et régional et de la recherche, Québec)
Intern; performed structural analysis; researched promotion of R&D

PUBLICATIONS

2021

Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, **Guérin A**, Kota V. Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. *Leuk Lymphoma*. 2021 Mar 1;1-14. doi: 10.1080/10428194.2021.1885656. Online ahead of print.

Chen L, Ionescu-Ittu R, Romdhani H, **Guérin A**, Kessler P, Borentain M, Friend K, DeSouza M, Sato N. Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan - Cardiology and Therapy. *Cardiol Ther*. 2021 Feb 20. doi: 10.1007/s40119-021-00212-y. Online ahead of print.

Greene SJ, Triana TS, Ionescu-Ittu R, Shi S, **Guérin A**, DeSouza MM, Kessler PD, Tugcu A, Borentain M, Felker GM. Patients Hospitalized for De Novo versus Worsening Chronic Heart Failure in the United States. *J Am Coll Cardiol*. 2021 Feb 23;77(7):1023-1025. doi: 10.1016/j.jacc.2020.12.026.

Gagnon-Sanschagrin P, Liang Y, Sanon M, Oberdhan D, **Guérin A**, Cloutier M. Excess Healthcare Costs in Patients with Autosomal Dominant Polycystic Kidney Disease by Renal Dysfunction Stage. *J Med Econ*. 2021 Jan-Dec;24(1):193-201. doi: 10.1080/13696998.2021.1877146.

Volk ML, Burne R, **Guérin A**, Shi S, Joseph GJ, Heimanson Z, Ahmad M. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States. *J Med Econ*. 2021 Jan-Dec;24(1):202-211. doi: 10.1080/13696998.2021.1877148.

Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, **Guérin A**, Wu EQ, Sadek I, Cao X. Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndrome Treated with Hypomethylating Agents: A SEER-Medicare Analysis. *J Med Econ*. 2021 Jan-Dec;24(1):234-243. doi: 10.1080/13696998.2021.1876714.

Blais MS, Meadows JA, Yu S, Robison DR, Hass SL, Norrett KE, **Guérin A**, Latremouille-Viau D, Tilles SA. Economic Burden of Peanut Allergy in Pediatric Patients with Evidence of Reactions to Peanut in the United States. *J Manag Care Spec Pharm*. 2021 Jan 20;1-12. doi: 10.18553/jmcp.2021.20389. Online ahead of print. PMID: 33470880.

Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, **Guérin A**, Wu EQ, Sadek I, Cao X. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. *Leuk Lymphoma*. 2021 Jan 11;1-16. doi: 10.1080/10428194.2020.1869959. Online ahead of print.

2020

Glick B, **Guérin A**, Ayyagari R, Lin T, Jacobson A, Joseph G, Kircik L. Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. *J Med Econ*. 2020. 23:6, 641-649. *J Med Econ*. 2020 Oct 12:1. doi: 10.1080/13696998.2020.1835305. Online ahead of print.

Aigbogun MS, Cloutier M, Gauthier-Loiselle M, **Guérin A**, Ladouceur M, Baker RA, Grundman M, Duffy RA, Hartry A, Gwin K, Fillit H. Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review. *J Alzheimers Dis*. 2020;77(3):1181-1194. doi: 10.3233/JAD-200127.

Shah NR, Bhor M, Latremouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Kumar Singh M, Serra E, Davidson M, Xu L, **Guérin A**. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid and Medicare Insurance - The perspective of private and public payers. *J Med Econ* 2020 Nov;23(11):1345-1355. doi: 10.1080/13696998.2020.1813144.

Greene SJ, Triana TS, Ionescu-Ittu R, Burne RM, **Guérin A**, Borentain M, Kessler PD, Tugcu A, DeSouza MM, Felker GM, Chen L. In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. *JACC Heart Fail.* 2020 Aug 12:S2213-1779(20)30383-8. doi: 10.1016/j.jchf.2020.05.013. Online ahead of print.

Cloutier M, Manceur AM, **Guérin A**, Aigbogun MS, Oberdhan D, Gauthier-Loiselle M. The societal economic burden of autosomal dominant polycystic kidney disease in the United States. *BMC Health Serv Res.* 2020 Feb 18;20(1):126. doi: 10.1186/s12913-020-4974-4.

2019

Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, **Guérin A**, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. *Melanoma Manag.* 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015.

Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, **Guérin A**, Hartry A, Baker RA, Duffy R, Gwin K, Sanon Aigbogun M. Institutionalization risk and costs associated with agitation in Alzheimer's disease. *Alzheimers Dement (NY).* 2019 Nov 23;5:851-861. doi: 10.1016/j.trci.2019.10.004. eCollection 2019.

Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, **Guérin A**, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. *Adv Ther* (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8. *Adv Ther.* 2019 Nov;36(11):2982-2985. doi: 10.1007/s12325-019-01088-0. Epub 2019 Sep 11.

Ionescu-Ittu R, Shang A, Velde NV, **Guérin A**, Lin Y, Shi L, Shi S, Qayum N. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world. *J Comp Eff Res.* 2019 Oct;8(13):1067-1075. doi: 10.2217/cer-2019-0062. Epub 2019 Aug 27. PMID: 31452397 Free article. <https://pubmed.ncbi.nlm.nih.gov/31452397/>.

Ionescu-Ittu R, Shang A, Vander Velde N, **Guérin A**, Lin Y, Shi L, Shi S, Qayum N. Comparable Overall Survival with Rituximab-Bendamustine (R-Benda) and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) When Used As Second-Line (2L) Treatment for Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World Study Using US Veterans Health Administration Data. *Blood Journal.* 2019. http://www.bloodjournal.org/content/132/Suppl_1/1711? Epub ahead of print.

Pennell N, Mutebi A, Zhou ZY, Ricculi ML, Tang W, Wang H, **Guérin A**, Arnhart T, Dalal A, Sasane M, Wu KY, Culver KW, Otterson GA. Economic Impact of Next Generation Sequencing vs. Single-gene Testing Strategies to Detect Genomic Alterations in Metastatic NSCLC Using a Decision Analytic Model. *JCO Precision Oncology.* 2019 May 16. doi: 10.1200/PO.18.00356. Epub ahead of print.

Dana R, Bradley JL, **Guérin A**, Pivneva I, Stillman IÖ, Evans AM, Schaumberg DA. Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System. *Am J Ophthalmol.* 2019 Jun;202:47-54.

Ritchie EK, Latremouille-Viau D, **Guérin A**, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL. Tyrosine Kinase Inhibitor Therapy Treatment and Discontinuation in Patients with Chronic Myeloid Leukemia in Chronic Phase in the United States: a Clinical Practice Perspective. *Leuk Lymphoma*. 2019 Jun;60(6):1476-1484.

Gauthier G, Mucha L, Shi S, **Guérin A**. Economic burden of relapse/recurrence in patients with major depressive disorder. *J Drug Assess*. 2019 May 24;8(1):97-103.

Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, **Guérin A**, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Survival, Motor Function, and Motor Milestones Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. *Adv Ther*. 2019 May;36(5):1164-1176.

Bradley JL, Özer Stillman I, Pivneva I, **Guérin A**, Evans AM, Dana R. Dry eye disease ranking among common reasons for seeking eye care in a large US claims database. *Clin Ophthalmol*. 2019 Feb 1;13:225-232.

Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, **Guérin A**, Li N, Joseph G. Cost-effectiveness of Midostaurin in the Treatment of Newly diagnosed FLT3-mutated Acute Myeloid Leukemia in the United States. *Pharmacoeconomics*. 2019 Feb;37(2):239-253.

Vander Velde N, **Guérin A**, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thåström A, Liu S, Shi L, Leppert JT. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. *Eur Urol Oncol*. 2019 Feb;2(1):12-20.

Lacy B, Ayyagari R, **Guérin A**, Lopez A, Shi S, Luo M. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. *Therap Adv Gastroenterol*. 2019 Jan 1;12:1756284818818326. doi: 10.1177/1756284818818326.

2018

Kimball AB, Sundaram M, Gauthier G, **Guérin A**, Pivneva I, Singh R, Ganguli A. The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis. *Dermatol Ther (Heidelb)*. 2018 Dec;8(4):557-569.

Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrín P, Arian D, Fleischer A, **Guérin A**, Ganguli A. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis. *J Drugs Dermatol*. 2018 Nov 1;17(11):1211-1218.

Seiter K, Latremouille-Viau D, **Guérin A**, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrín P, Joseph GJ. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. *Adv Ther*. 2018 Oct;35(10):1671-1685.

Dana R, Bradley JL, **Guérin A**, Pivneva I, Evans AM, Stillman IÖ. Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study. *Am J Ophthalmol*. 2019 Feb;198:181-192. doi: 10.1016/j.ajo.2018.10.001. Epub 2018 Oct 9.

Cloutier M, Greene M, Touya M, Gagnon-Sanschagrín P, **Guérin A**. A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States. *J Med Econ*. 2018 Sep 26:1-8.

Stein EM, Yang M, **Guérin A**, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ. Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States. *Health Qual Life Outcomes*. 2018 Sep 21;16(1):193.

Dalal AA, Gauthier G, Gagnon-Sanschagrín P, Burne R, **Guérin A**, Niravath P, Small T. Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer. *Adv Ther.* 2018 Sep;35(9):1356-1367.

Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrín P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA. Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer. *Adv Ther.* 2018 Aug;35(8):1251-1264.

Reyes C, Gauthier G, Shi S, **Guérin A**. Overall Survival and Health Care Costs of Medicare Patients with Previously Treated Chronic Lymphocytic Leukemia. *Journal of Cancer Therapy.* Vol.9 No.7, July 2018.

Dalal AA, Gagnon-Sanschagrín P, Burne R, **Guérin A**, Gauthier G, Small T, Niravath P. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer. *Adv Ther.* 2018 Jun;35(6):768-778.

Borghaei H, Yim YM, **Guérin A**, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. *Lung Cancer.* 2018 May;119:112-119.

Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrín P, **Guérin A**. Assessment of costs associated with adverse events in patients with cancer. *PLoS One.* 2018 Apr 13;13(4):e0196007.

Gauthier G, Gagnon-Sanschagrín P, **Guérin A**, Burne R, Small T, Niravath P, Dalal AA. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women. *Adv Ther.* 2018 Apr;35(4):503-514.

Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, **Guérin A**, Gauthier G, Wu EQ, Niravath P, Small T. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study. *Adv Ther.* 2018 Apr;35(4):482-493.

Dalal AA, **Guérin A**, Mutebi A, Culver KW. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. *J Med Econ.* 2018 Mar 26:1-7.

Dalal AA, **Guérin A**, Mutebi A, Culver KW. Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis. *J Drug Assess.* 2018 Mar 12;7(1):21-27.

Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrín P, **Guérin A**, Ganguli A. Increased Prevalence of Cancer in Adult Patients with Psoriasis in the United States: A Claims Based Analysis. *J Drugs Dermatol.* 2018 Feb 1;17(2):180-186.

Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, **Guérin A**. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan. *J Dermatolog Treat.* 2018 Feb;29(1):24-31.

Nellesen D, Dea K, **Guérin A**, Culver KW, Mutebi A, Dalal AA. Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC). *Am J Manag Care.* 2018 Feb;24(2 Spec No.):SP37-SP42. <http://www.ajmc.com/journals/evidence-based-oncology/2018/february-2018/reimbursement-landscape-for-molecular-testing-in-nonsmall-cell-lung-cancer?p=1>.

Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, **Guérin A**, Singh R, Ganguli A. The Risk of Cardiovascular Events in Psoriasis Patients Treated with Tumor Necrosis Factor-alpha Inhibitors

versus Phototherapy: A Large Observational Cohort Study. *J Am Acad Dermatol*. 2018 Feb 27. pii: S0190-9622(18)30335-9.

Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, **Guérin A**, Ganguli A. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. *J Drugs Dermatol*. 2018 Feb 1;17(2):187-194.

Stein EM, Bonifacio G, Latremouille-Viau D, **Guérin A**, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ. Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Acute Myeloid Leukemia in Commercially Insured and Medicare Populations. *J Med Econ*. 2018 Jan 5:1-17.

2017

Johnson DR, Omuro AMP, Ravelo A, Sommer N, **Guérin A**, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH. Overall survival in patients with glioblastoma before and after bevacizumab approval. *Curr Med Res Opin*. 2017 Nov 10:1-8.

Yang H, Duchesneau E, Foster R, **Guérin A**, Ma E, Thomas NP. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. *J Med Econ*. 2017 Oct;20(10):1056-1065.

Maziarz RT, Hao Y, **Guérin A**, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2017 Sep 21:1-10.

Cloutier M, Greene M, **Guérin A**, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. *J Affect Disord*. 2017 Sep 14;226:45-51.

Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, **Guérin A**. Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients. *Adv Ther*. 2017 Jul;34(7):1673-1685.

Gauthier G, **Guérin A**, Zhdanova M, Jacobson W, Nomikos G, Merikle E, François C, Perez V. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis. *BMC Psychiatry*. 2017 Jun 19;17(1):222.

Wu JJ, **Guérin A**, Gauthier G, Sundaram M. Healthcare Resource Utilization, Healthcare Costs, and Dose Escalation in Psoriasis Patients Initiated on Ustekinumab versus Adalimumab: A Retrospective Claim Study. *J Dermatolog Treat*. 2017 Jun;28(4):290-298.

Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, **Guérin A**. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study. *Adv Ther*. 2017 May;34(5):1145-1156.

Li N, Yang X, Fan L, Totev T, **Guérin A**, Chen L, Bhattacharyya S, Joseph G. Nilotinib versus Dasatinib as Second-Line Therapy in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis Based on Real-World Data. *J Med Econ*. 2017 Apr;20(4):328-336.

Bollu V, **Guérin A**, Gauthier G, Hiscock R, Wu EQ. Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β_2 -Agonists. *Drugs Real World Outcomes*. 2017 Mar;4(1):33-41.

Ritchie EK, **Guérin A**, Wolff J, Joseph G. Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia. *J Clin Oncol*. 2017 May 20;35(15):1744-1745. doi: 10.1200/JCO.2016.72.0011. Advance online publication 2017 Feb 13. No abstract available.

Latremouille-Viau D, **Guérin A**, Gagnon-Sanschagrín P, Dea K, Cohen BG, Joseph GJ. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. *J Manag Care Spec Pharm*. 2017 Feb;23(2):214-224.

Wu JJ, **Guérin A**, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor- α inhibitors versus methotrexate. *J Am Acad Dermatol*. 2017 Jan;76(1):81-90.

Latremouille-Viau D, **Guérin A**, Nitulescu R, Gagnon PS, Joseph GJ, Chen L. Treatment Patterns and Healthcare Costs among Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as First-Line Therapy in the United States. *J Med Econ*. 2017 Jan;20(1):63-71.

Latremouille-Viau D, Chang J, **Guérin A**, Shi S, Wang E, Yu J, Ngai C. The Economic Burden of Common Adverse Events Associated with Metastatic Colorectal Cancer Treatment in the United States. *J Med Econ*. 2017 Jan;20(1):54-62.

2016

Jemec GB, **Guérin A**, Kaminsky M, Okun M, Sundaram M. What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis. *J Med Econ*. 2016 Jul;19(7):710-7.

Cloutier M, Sanon Aigbogun M, **Guérin A**, Nitulescu R, Ramanakumar AV, Kamat SA, DeLucia M, Duffy R, Legacy SN, Henderson C, Francois C, Wu E. The Economic Burden of Schizophrenia in the United States in 2013. *J Clin Psychiatry*. 2016 Jun;77(6):764-71.

Guérin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. *Expert Opin Pharmacother*. 2016 Jun;17(9):1189-96.

Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, **Guérin A**. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. *Adv Ther*. 2016 Jun;33(6):983-97.

Gallagher CM, More K, Kamath T, Masaquel A, **Guérin A**, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B. Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. *Breast Cancer Res Treat*. 2016 May;157(1):145-56.

Maziarz RT, **Guérin A**, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L. Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell

transplant. *International Journal of Hematologic Oncology*. Advance online publication 2016 Apr 27. doi: 10.2217/ijh-2016-0001.

Lacy BE, Patel H, **Guérin A**, Dea K, Scopel JL, Alaghband R, Wu EQ, Mody R. Variation in Care for Patients with Irritable Bowel Syndrome in the United States. *PLoS One*. 2016 Apr 26;11(4):e0154258.

Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, **Guérin A**. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. *J Med Econ*. 2016 Apr;19(4):414-23.

Gallagher CM, More K, Masaquel A, Kamath T, **Guérin A**, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B. Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice. *Springerplus*. 2016 Mar 31;5:395.

Joseph A, Cloutier M, **Guérin A**, Nitulescu R, Sikirica V. Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine or atomoxetine. *Patient Prefer Adherence*. 2016 Mar 24;10:391-405.

Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, **Guérin A**. Time on treatment of everolimus and chemotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: A retrospective claims study in the US. *Curr Med Res Opin*. 2015 Dec 10:1-32. *Curr Med Res Opin*. 2016 Feb;32(2):385-94.

Smith BD, Liu J, Latremouille-Viau D, **Guérin A**, Fernandez D, Chen L. Treatment Patterns, Overall Survival, Healthcare Resource Use and Costs in Elderly Medicare Beneficiaries with Chronic Myeloid Leukemia using Second-Generation Tyrosine Kinase Inhibitors as Second-Line Therapy. *Curr Med Res Opin* 2016 32(5): 817-827. Advance online publication 2016 Jan 9; doi: 10.1185/03007995.2016.1140030.

Guérin A, Mody R, Carter V, Ayas C, Patel H, Lasch K, Wu E. Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication. *PLoS One*. 2016 Jan 4;11(1):e0145504.

Guérin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Macalalad AR. The economic burden of brain metastasis among lung cancer patients in the United States. *J. Med. Econ*. 2016 05; 19(5): 526-536. doi: 10.3111/13696998.2016.1138962.

2015

Guérin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection. *JAMA Oncol*. 2015 Sep;1(6):797-805.

Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, **Guérin A**, Yim YM. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. *Cancer Med*. 2015 Aug;4(8):1205-13.

Guérin A, Sasane M, Wakelee H, Zhang J, Culver K, Dea K, Nitulescu R, Galebach P, Macalalad AR. Treatment, overall survival and costs in patients with ALK+ non-small cell lung cancer after crizotinib monotherapy. *Curr Med Res Opin*. 2015 Aug;31(8):1587-97.

Shiozawa A, Cloutier M, Heroux J, **Guérin A**, Wu EQ, Jackson R. Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study. *Curr Med Res Opin*. 2015 Aug;31(8):1611-20.

Armstrong AW, **Guérin A**, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. *J Am Acad Dermatol*. 2015 Jun;72(6):968-977.

Guérin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. *Cancer Epidemiol*. 2015 Jun;39(3):307-12.

Guérin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. *J Med Econ*. 2015 Apr;18(4):312-22.

Guérin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ. The Economic Burden of Gastrointestinal Stromal Tumor (GIST) Recurrence in Patients Who Have Received Adjuvant Imatinib Therapy. *J Med Econ*. 2015 Mar;18(3):241-8.

2014

Conley AP, **Guérin A**, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. Treatment Patterns, Prescribing Decision Drivers, and Predictors of Complete Response Following Disease Recurrence in Gastrointestinal Stromal Tumor Patients-a Chart Extract-Based Approach. *J Gastrointest Cancer*. 2014 Dec;45(4):431-40.

Langer C, Ravelo A, Hazard SJ, **Guérin A**, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: A retrospective cohort study. *Lung Cancer*. 2014 Dec;86(3):350-7.

Mody R, **Guérin A**, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. Prevalence and Risk of Developing Comorbid Conditions in Patients with Chronic Constipation. *Curr Med Res Opin*. 2014 Dec;30(12):2505-2513.

Guérin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. *Curr Med Res Opin*. 2014 Nov;30(11):2317-28.

Loftus EV Jr, Skup M, Ozbay AB, Wu E, **Guérin A**, Chao J, Mulani P. The Impact of Moderate-to-severe Crohn's Disease on Employees' Salary Growth. *Inflamm Bowel Dis*. 2014 Oct;20(10):1734-8.

Bron M, **Guérin A**, Latremouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, Wu EQ. Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. *J Med Econ*. 2014 Sep;17(9):646-57.

Hurvitz S, **Guérin A**, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D. Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting. *Oncologist*. 2014 Sep;19(9):901-8.

Guérin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E. The Economic Burden of Treatment Failure Among Patients with Irritable Bowel Syndrome with Constipation or Chronic Constipation: A Retrospective Analysis of a Medicaid Population. *J Med Econ*. 2014 Aug;17(8):577-86.

Deangelo DJ, Chen L, **Guérin A**, Styles A, Giguere-Duval P, Wu EQ. Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis. *Clin Lymphoma Myeloma Leuk*. 2014 Jun;14(3):245-51.

Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. *Curr Med Res Opin*. 2014 Jul;30(7):1345-52.

Guérin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. *Aliment Pharmacol Ther*. 2014 Jul;40(1):83-92.

Guérin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG. Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis. *Springerplus*. 2014 May 8;3:236.

Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Economic Benefits of Adequate Molecular Monitoring in Patients with Chronic Myelogenous Leukemia. *J Med Econ*. 2014 Feb;17(2):89-98.

Ben Amor L, Sikirica V, Cloutier M, Lachaine J, **Guérin A**, Carter V, Hodgkins P, van Stralen J. Combination and switching of stimulants in children and adolescents with ADHD in Quebec. *J Can Acad Child Adoles Psychiatry*. 2014;23(3):157-166.

2013

Setyawan J, **Guérin A**, Hodgkins P, Gauthier G, Cloutier M, Wu E, Haim Erder M. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications. *J Med Econ*. 2013 Nov;16(11):1275-89.

Setyawan J, Hodgkins P, **Guérin A**, Gauthier G, Cloutier M, Wu E, Erder MH. Comparison of Therapy Augmentation and Deviation Rates from the Recommended Once-Daily Dosing Regimen between LDX and Commonly Prescribed Long-Acting Stimulants for the Treatment of ADHD in Youth and Adults. *J Med Econ*. 2013 Oct;16(10):1203-15.

Goldberg SL, Chen L, **Guérin A**, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ. Association between Molecular Monitoring and Long Term Outcomes in Chronic Myelogenous Leukemia Patients Treated with First Line Imatinib. *Curr Med Res Opin*. 2013 Sep;29(9):1075-82.

Guérin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS. Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. *Int J Cardiol*. 2013 Jul 31;167(2):564-9.

Kan H, **Guérin A**, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C. A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. *J Med Econ*. 2013 Jul;16(7):962-75.

Setyawan J, Hodgkins P, **Guérin A**, Gauthier G, Cloutier M, Wu EQ, Haim Erder M. Comparing Treatment Adherence of Lisdexamfetamine and Other Medications for the Treatment of Attention Deficit/Hyperactivity Disorder: A Retrospective Analysis. *J Med Econ*. 2013 Jul;16(7):962-75.

Conley AP, **Guérin A**, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy-A Retrospective Chart Extract-Based Approach. *J Gastrointest Cancer*. 2013 Jun;44(2):190-8.

Griffin JD, **Guérin A**, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis. *Curr Med Res Opin.* 2013 Jun;29(6):623-31.

Guérin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A. The Economic Burden of Pleural Effusions in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors. *J Med Econ.* 2013;16(1):125-33.

2012

Strober BE, Sobell JM, Duffin KC, Bao Y, **Guérin A**, Yang H, Goldblum O, Okun MM, Mulani PM. Sleep quality and other patient-reported outcomes improve after psoriasis patients with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. *Br J Dermatol.* 2012 Dec;167(6):1374-81.

Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, **Guérin A**. Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors. *J Med Econ.* 2012 Nov 16. 2013;16(2):221-30.

Chen L, **Guérin A**, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E. Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. *Curr Med Res Opin.* 2012 Nov;28(11):1831-9.

Wu EQ, Forsythe A, **Guérin A**, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. *Am J Ther.* 2012 Nov;19(6):e157-66.

Kimball AB, Wu EQ, **Guérin A**, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM. Risks of developing psychiatric disorders in pediatric patients with psoriasis. *J Am Acad Dermatol.* 2012 Oct;67(4):651-7.e1-2.

Helmerts SL, Duh MS, **Guérin A**, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. *Eur J Paediatr Neurol.* 2012 Sep;16(5):449-58.

Guérin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. *Curr Med Res Opin.* 2012 Jul;28(7):1155-62.

Cella D, Pickard AS, Duh MS, **Guérin A**, Mishagina N, Antràs L, Neary MP, McCann L, Hodge R, Sternberg CN. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. *Eur J Cancer.* 2012 Feb;48(3):311-23.

2011

Yu AP, **Guérin A**, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. *Respir Med.* 2011 Dec;105(12):1861-71.

Helmerts SL, Duh MS, **Guérin A**, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. *Epilepsy Behav.* 2011 Oct;22(2):370-5.

Loftus EV Jr, **Guérin A**, Yu AP, Wu EQ, Yang M, Chao J, Mulani PM. Increased Risks of Developing Anxiety and Depression in Young Patients With Crohn's Disease. *Am J Gastroenterol*. 2011 Sep;106(9):1670-7.

Yu AP, **Guérin A**, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. *J Med Econ*. 2011 June;14(4):486-96.

Kimball AB, Bensimon AG, **Guérin A**, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. *Am J Clin Dermatol*. 2011 Feb 1;12(1):51-62.

Kimball AB, **Guérin A**, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. Economic Burden of Comorbidities in Patients with Psoriasis Is Substantial. *J Eur Acad Dermatol Venereol*. 2011 Feb;25(2):157-163.

Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, **Guérin A**, Boerstoeel-Streefland M, Jiang W, Lefebvre P. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. *Ann Pharmacother*. 2011 Feb;45(2):179-88.

Duh MS, Greenberg PE, **Guérin A**, Korves C. Mortality and nonadherence to AEDs (chapter), *Sudden Unexpected Death in Epilepsy: Continuing the Global Conversation*, a publication of Epilepsy Australia, Epilepsy Bereaved, and SUDEP Aware/North America, 2011.

2010

Wu EQ, **Guérin A**, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. *Curr Med Res Opin*. 2010 Dec;26(12):2861-9.

Frois C, **Guérin A**, Saraogi A, Panish J, Dirani R. Perceptions and prescribing considerations among US psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics. *Curr Med Res Opin*. 2010 Dec;26(12):2735-44.

Kimball AB, **Guérin A**, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P. Coronary Heart Disease and Stroke Risk in Patients with Psoriasis: Retrospective Analysis. *Am J Med*. 2010 Apr;123(4):350-357.

Saurat JH, **Guérin A**, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM. High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice. *Dermatology*. 2010;220(2):128-37.

2009

Faught RE, Weiner JR, **Guérin A**, Cunnington MC, Duh MS. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: Findings from the RANSOM study. *Epilepsia*. 2009 Mar;50(3):501-9.

Loftus EV, **Guérin A**, Tsaneva M, Yu AP, Chao JD, Mulani P. Direct and Indirect Economic Burdens and Impact on Salary Growth of Moderate to Severe Crohn's Disease. *Gastroenterology*. 2009; 136(5):A-26-27.

2008

Faught E, Duh MS, Weiner JR, **Guérin A**, Cunnington MC., Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study, *Neurology*. 2008 Nov 11;71(20):1564-5.

Cost-Effectiveness Analysis of Different Hormonal Therapies in Breast Cancer in Women (master's thesis), Université de Sherbrooke, Quebec, 2008.

LANGUAGES

French (native)

English (fluent)